Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

Fernandez S, Desplat V, Villacreces A, Guitart AV, Milpied N, Pigneux A, Vigon I, Pasquet JM, Dumas PY.

Int J Mol Sci. 2019 Jul 12;20(14). pii: E3429. doi: 10.3390/ijms20143429. Review.

2.

Effects of Ultra-Low-Dose Aspirin in Thrombosis and Haemorrhage.

Eizayaga FX, Belon P, Desplat V, Aguejouf O, Doutremepuich C.

Homeopathy. 2019 Aug;108(3):158-168. doi: 10.1055/s-0038-1677495. Epub 2019 Apr 20.

PMID:
31005060
3.

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.

Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM.

Haematologica. 2019 Oct;104(10):2017-2027. doi: 10.3324/haematol.2018.205385. Epub 2019 Mar 28.

4.

Design, Synthesis and Biological Evaluation of New Substituted Diquinolinyl-Pyridine Ligands as Anticancer Agents by Targeting G-Quadruplex.

Das RN, Chevret E, Desplat V, Rubio S, Mergny JL, Guillon J.

Molecules. 2017 Dec 30;23(1). pii: E81. doi: 10.3390/molecules23010081.

5.

Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence.

Ianniciello A, Dumas PY, Drullion C, Guitart A, Villacreces A, Peytour Y, Chevaleyre J, Brunet de la Grange P, Vigon I, Desplat V, Priault M, Sbarba PD, Ivanovic Z, Mahon FX, Pasquet JM.

Oncotarget. 2017 Jun 30;8(57):96984-96992. doi: 10.18632/oncotarget.18904. eCollection 2017 Nov 14.

6.

Synthesis and Antiproliferative Effect of Ethyl 4-[4-(4-Substituted Piperidin-1-yl)]benzylpyrrolo[1,2-a]quinoxalinecarboxylate Derivatives on Human Leukemia Cells.

Desplat V, Vincenzi M, Lucas R, Moreau S, Savrimoutou S, Rubio S, Pinaud N, Bigat D, Enriquez E, Marchivie M, Routier S, Sonnet P, Rossi F, Ronga L, Guillon J.

ChemMedChem. 2017 Jun 21;12(12):940-953. doi: 10.1002/cmdc.201700049. Epub 2017 Apr 5.

PMID:
28218826
7.

Design, Synthesis, and Evaluation of 2,9-Bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline Derivatives as G-Quadruplex Ligands.

Gueddouda NM, Hurtado MR, Moreau S, Ronga L, Das RN, Savrimoutou S, Rubio S, Marchand A, Mendoza O, Marchivie M, Elmi L, Chansavang A, Desplat V, Gabelica V, Bourdoncle A, Mergny JL, Guillon J.

ChemMedChem. 2017 Jan 20;12(2):146-160. doi: 10.1002/cmdc.201600511. Epub 2017 Jan 3.

8.

Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines.

Desplat V, Vincenzi M, Lucas R, Moreau S, Savrimoutou S, Pinaud N, Lesbordes J, Peyrilles E, Marchivie M, Routier S, Sonnet P, Rossi F, Ronga L, Guillon J.

Eur J Med Chem. 2016 May 4;113:214-27. doi: 10.1016/j.ejmech.2016.02.047. Epub 2016 Feb 20.

PMID:
26945110
9.

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.

Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM.

J Pathol. 2015 Sep;237(1):14-24. doi: 10.1002/path.4561. Epub 2015 Jun 4.

PMID:
25965880
10.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.

PMID:
24677542
11.

Aspirin discontinuation syndromes: clinical implications of basic research studies.

Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX.

Am J Cardiovasc Drugs. 2013 Dec;13(6):377-84. doi: 10.1007/s40256-013-0044-1.

PMID:
24045958
12.

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.

Guillon J, Le Borgne M, Rimbault C, Moreau S, Savrimoutou S, Pinaud N, Baratin S, Marchivie M, Roche S, Bollacke A, Pecci A, Alvarez L, Desplat V, Jose J.

Eur J Med Chem. 2013 Jul;65:205-22. doi: 10.1016/j.ejmech.2013.04.051. Epub 2013 May 3.

PMID:
23711832
13.

Basis of a FTIR spectroscopy methodology for automated evaluation of Akt kinase inhibitor on leukemic cell lines used as model.

Travo A, Desplat V, Barron E, Poychicot-Coustau E, Guillon J, Déléris G, Forfar I.

Anal Bioanal Chem. 2012 Oct;404(6-7):1733-43. doi: 10.1007/s00216-012-6283-1. Epub 2012 Aug 1.

PMID:
22850898
14.

Paradoxical effect of aspirin.

Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX.

Thrombosis. 2012;2012:676237. doi: 10.1155/2012/676237. Epub 2012 Jan 15.

15.

Thrombotic events associated to aspirin therapy.

Doutremepuich C, Aguejouf O, Desplat V, Duprat D, Eizayaga FX.

Thrombosis. 2012;2012:247363. doi: 10.1155/2012/247363. Epub 2011 Nov 24.

16.

New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity--Part II.

Guillon J, Mouray E, Moreau S, Mullié C, Forfar I, Desplat V, Belisle-Fabre S, Pinaud N, Ravanello F, Le-Naour A, Léger JM, Gosmann G, Jarry C, Déléris G, Sonnet P, Grellier P.

Eur J Med Chem. 2011 Jun;46(6):2310-26. doi: 10.1016/j.ejmech.2011.03.014. Epub 2011 Mar 15.

PMID:
21458112
17.

Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.

Desplat V, Moreau S, Belisle-Fabre S, Thiolat D, Uranga J, Lucas R, de Moor L, Massip S, Jarry C, Mossalayi DM, Sonnet P, Déléris G, Guillon J.

J Enzyme Inhib Med Chem. 2011 Oct;26(5):657-67. doi: 10.3109/14756366.2010.548326. Epub 2011 Jan 21.

PMID:
21250818
18.

Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.

Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX.

Cardiovasc Hematol Disord Drug Targets. 2010 Jun;10(2):103-10.

PMID:
20350286
19.

Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II.

Desplat V, Moreau S, Gay A, Fabre SB, Thiolat D, Massip S, Macky G, Godde F, Mossalayi D, Jarry C, Guillon J.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):204-15. doi: 10.3109/14756360903169881.

PMID:
20222763
20.

Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation.

Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX.

Thromb Haemost. 2010 Jan;103(1):171-80. doi: 10.1160/TH09-07-0506. Epub 2009 Nov 13.

PMID:
20062937

Supplemental Content

Loading ...
Support Center